• Health: A practical guide to know everything about vaccination

The German company

BionTech

, who developed the first vaccine against the coronavirus with the US consortium

Pfizer

will increase production to meet the needs of the countries of the

EU

, in which there is at the

moment a shortage to achieve immunize the entire population.

In an interview with

Der Spiegel

magazine,

the CEO of BioNTech attributed the current shortage in part to the EU purchasing policy in which the process has been slower than in other parts of the world. "The process in Europe was not as bad. fast and direct as in other countries and this is also due to the fact that the EU did not authorize the orders directly but the member countries also had a voice. In a negotiation in which a clear announcement is required, this is something that can take time " said

Sahin

to

Der Spiegel

.

"There was the assumption that many other companies would come with vaccines. Apparently there was the impression that there would be enough and that things would not be serious, that surprised me," he added.

That has led, according to Sahin, to a shortage because "other authorized vaccines are lacking and we will have to fill the gap with our vaccine."

Sahin's interview comes as

Germany

has been criticized for the slowness of the vaccination campaign that began on December 27.

The medical director of BioNTech,

Ózlem Türeci

, said, for her part, that the idea of ​​creating a kind of basket with vaccines from different producers was in principle correct, but the moment came when it was seen that many could not comply with the orders.

Increasing production, according to Türeci, is not easy since "it is not that there are specialized factories all over the world that can produce overnight with the necessary quality.

BioNTech has already commissioned five manufacturers in Europe to produce the vaccine and is negotiating new contracts.

Sahin is hopeful about the effect that a new factory in

Marburg

(central Germany) will have, which may enable 250 million doses to be produced in the first half.

According to the criteria of The Trust Project

Know more

  • Vaccinations

  • Coronavirus

  • Covid 19

  • Science and Health

Health "We cannot happily launch ourselves to vaccinate when there has been no preparation and personal lack"

The US confirms the efficacy of the Pfizer vaccine and 'The Lancet' endorses that of AstraZeneca

SaludSanidad still does not know how it will distribute the doses in the CCAA five days after starting the vaccination

See links of interest

  • Check Christmas Lottery

  • Check Child Lottery

  • Athletic Club - Real Sociedad

  • Osasuna - Alaves